✦ LIBER ✦

A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies

✍ Scribed by Jonathan W Goldman, Robert N Raju, Gregory A Gordon, Iman El-Hariry…

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

1230 POSTER A Phase 1 and Pharmacokineti

✍ R.D. Harvey; C.M. Lewis; J.S. Kauh; T.K. Owonikoko; A. Akintayo; M. Karol; F. Te 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 43 KB

570 A phase I study to determine the saf

✍ H. Burris III; P. LoRusso; S. Jones; J. McCormick; N. Willcutt; J. Hodge; P. Bus 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 327 KB

A Phase 1 dose-escalation study of the s

✍ Shapiro, Geoffrey I.; McCallum, Stewart; Adams, Laurel M.; Sherman, Laurie; Well 📂 Article 📅 2012 🏛 Springer US 🌐 English ⚖ 260 KB

Phase I study of the safety, tolerabilit

✍ Glen J. Weiss, Manuel Hidalgo, Mitesh J. Borad, Daniel Laheru, Raoul Tibes, Rame 📂 Article 📅 2011 🏛 Springer US 🌐 English ⚖ 393 KB

A phase I study of the safety and pharma

✍ Herbert I. Hurwitz; Roger B. Cohen; J. Patrick McGovren; Samit Hirawat; William 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 308 KB

601 A First-in-human, Phase 1 Clinical S

✍ Mahalingam, D.; Wilding, G.; Denmeade, S.; Sarantopoulas, J.; Cosgrove, D.; Cetn 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 79 KB